The provision of Tamoxifen as chemoprevention in a family history clinic
Association of Breast Surgery ePoster Library. Foster K. 05/15/17; 166180; P112
Mrs. Kate Foster
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Background:
NICE Guidance issued in 2004 (updated 2006 and 2013) for the management of women with a family history of breast cancer led to the establishment of a breast cancer family history clinic at Princess Alexandra Hospitals NHS Trust. Following the guidance update in 2013, we began offering our patients Tamoxifen as a risk-reducing measure.
Materials & Methods:
The clinic was set up in 2006 with a research grant from the QUEST cancer research charity. Women with a family history of breast cancer are referred to this clinic for assessment. Using the NICE guidance the patients are categorised into population, moderate and high risk groups. From July 2014, women in the increased risk groups were considered for suitability for Tamoxifen as a risk-reducing measure. They were given verbal and written information (provided by Cancer Genetics Group)
Results:
Between 1/7/2014-31/10/16 153 women were offered Tamoxifen as a risk-reducing measure. 42% were assessed as moderate risk and 58% high risk.
Of the 153 offered Tamoxifen, 16% went onto commence chemoprevention. 84% of these patients continue to take Tamoxifen. 4 women stopped taking the drug at periods varying between 1.5 and 7.5 months. All did so because of side effects. All these women were in the high risk category.
Conclusion:
We continue to provide chemoprevention information and prescribe Tamoxifen.
We are also taking part in The ENGAGE study.
References:
1. Clinical Guideline (CG14) Published date:October 2006 www.nice.org.uk/guidance/cg14
2. Full Guideline.http://www.nice.org/nicemedia/pdf/CG164fullguidancepdf
3. http://www.ukcgg.org/information-education/
Background:
NICE Guidance issued in 2004 (updated 2006 and 2013) for the management of women with a family history of breast cancer led to the establishment of a breast cancer family history clinic at Princess Alexandra Hospitals NHS Trust. Following the guidance update in 2013, we began offering our patients Tamoxifen as a risk-reducing measure.
Materials & Methods:
The clinic was set up in 2006 with a research grant from the QUEST cancer research charity. Women with a family history of breast cancer are referred to this clinic for assessment. Using the NICE guidance the patients are categorised into population, moderate and high risk groups. From July 2014, women in the increased risk groups were considered for suitability for Tamoxifen as a risk-reducing measure. They were given verbal and written information (provided by Cancer Genetics Group)
Results:
Between 1/7/2014-31/10/16 153 women were offered Tamoxifen as a risk-reducing measure. 42% were assessed as moderate risk and 58% high risk.
Of the 153 offered Tamoxifen, 16% went onto commence chemoprevention. 84% of these patients continue to take Tamoxifen. 4 women stopped taking the drug at periods varying between 1.5 and 7.5 months. All did so because of side effects. All these women were in the high risk category.
Conclusion:
We continue to provide chemoprevention information and prescribe Tamoxifen.
We are also taking part in The ENGAGE study.
References:
1. Clinical Guideline (CG14) Published date:October 2006 www.nice.org.uk/guidance/cg14
2. Full Guideline.http://www.nice.org/nicemedia/pdf/CG164fullguidancepdf
3. http://www.ukcgg.org/information-education/
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}